JAK Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Janus Kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. There are four JAK family members; JAK1, JAk2, JAk3, TYK2. The molecules that use the JAK/STAT signaling pathway are colony-stimulating factor, prolactin, growth hormone, and many cytokines. The mechanism of action (MOA) of the JAK inhibitors inhibitors involves the inhibition of one or more of the JAK enzymes, particularly JAK1, JAK2, JAK3, or TYK2. By blocking these enzymes, JAK inhibitors interfere with the signaling cascades triggered by cytokines, such as interleukins and interferons. When a cytokine binds to its respective receptor on the cell surface, it activates the associated JAK enzymes. The activated JAKs, in turn, phosphorylate (add a phosphate group to) specific signal transducer and activator of transcription (STAT) proteins. These phosphorylated STATs then dimerize, translocate to the nucleus, and regulate gene expression.

By inhibiting JAK enzymes, JAK inhibitors prevent the phosphorylation of STAT proteins and their subsequent nuclear translocation. This interruption of the JAK-STAT signaling pathway leads to the inhibition of the expression of pro-inflammatory genes and the modulation of immune responses. JAK inhibitors are used in the treatment of blood coagulation disorder, lymphoma, autoimmune disorder, rheumatoid arthritis, skin diseases, connective tissue diseases, neoplasms, etc. Increased prevalence of inflammatory conditions, such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, and rising aging population, etc are the key drivers for the JAK inhibitor market. For instance, according to the Centers for Disease Control and Prevention, an estimated 1.3% of US adults (3 million) reported being diagnosed with IBD; either Crohn's disease or ulcerative colitis. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in JAK inhibitors. For instance, BMS launched the Sotyktu (Deucravacitinib)  for the treatment of plaque psoriasis.  Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instances, Incyte’s Itacitinib (INCB039110) for the indication of B cell lymphoma is under the various stages of clinical studies.

Key Market Developments:

• In September 2022, Bristol Myers Squibb has received FDA approval for its Sotyktu (Deucravacitinib) tablets for treatment of adults with moderate-to-severe plaque psoriasis.  
• In May 2023, AbbVie has received FDA approval for its JAK Inhibitors molecule Rinvoq (Upadacitinib) for the additional indication of adults with moderately to severely active Crohn's disease.

Approved Drug Molecules and Brand Names for JAK Inhibitors Market:

• Jakafi (Ruxolitinib)
• Olumiant (Baricitinib)
• Rinvoq (Upadacitinib)
• Sotyktu (Deucravacitinib) Tablets
• Cibinqo (Abrocitinib)
• Vonjo (Pacritinib)
• Opzelura (Ruxolitinib) Cream 1.5%
• Litfulo (Ritlecitinib)
• Inrebic (Fedratinib)
• Gavreto (Pralsetinib)

Drugs under the Pipeline for JAK Inhibitors:

• Itacitinib (INCB039110)
• Ivarmacitinib (SHR0302)
• Deuruxolitinib (CTP-543)
• Brepocitinib (PF-06700841)
• Corectim (delgocitinib)
• Momelotinib (GSK3070785)
• Lestaurtinib (CEP-701)
• Povorcitinib (INCB54707)
• Izencitinib (TD-1473)
• GLPG3667
• Max-40279
• Repotrectinib (TPX-0005)
• Zotiraciclib (TG02)
• Gusacitinib (ASN002)
• Ifidancitinib (ATI-502)
• Solcitinib (GSK2586184)
• AT9283
• TLL018
• Decernotinib (VX-509)
• Ropsacitinib (PF-06826647)
• BMS-986322
• LNK01001
• TQ05105
• Golidocitinib (DZD4205)
• Tinengotinib (TT-00420)
• ESK-001
• INCB47986
• VC005
• Dubermatinib (TP-0903)
• Gandotinib (LY 2784544)
• AZD1480
• GLPG0555
• IN-A002
• R 348
• VTX958
• WP1066
• Cerdulatinib (ALXN2075)
• Nezulcitinib (TD-0903)
• AQ280
• ATI-1777
• ATI-50001
• BGB-23339
• CPL'116
• FTP-637
• GLPG-3121
• ICP-332
• INCB052793
• KN-002
• PF-06263276
• SYHX1901
• TAK-279
• TD-8236
• XL019
• Ilginatinib (NS-018)
• Ivarmacitinib Cream (ARQ-252)
• Lorpucitinib (JNJ-64251330)
• 15N2-Tofacitinib (TD-3504)
• A223
• AC430
• AZD4604
• BMS-911543
• CEE321
• CS12192
• FZJ-003
• GDC 4379
• GDC-0214
• ICP-488
• MAX-40070
• ONX 0805
• OST-122
• PF-07259955
• PF-07295324

Clinical Activity and Developments of JAK Inhibitors:

Up until July 2023, there will be more than 50 companies with over 180 compounds that focus on various forms rheumatoid arthritis, and hematologic diseases. For these molecules, more than 1,500 of clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,

• In June 2023, Jiangsu Hengrui Medicine is conducting phase 1 clinical study of Ivarmacitinib (SHR0302) oral solution and tablets to evaluate Relative Bioavailability in Healthy Subjects.
• In May 2023, Concert Pharmceuticals has completed phase 2 clinical study of Deuruxolitinib (CTP-543) to evaluate maintenance of hair regrowth following dose reduction of CTP-543 in adult patients with moderate to severe alopecia areata.